Cabaletta Bio
176 employees
Biotech/Pharma
Public · $88.3M
Open positions (18)
Company details
Team Size176
IndustryBiotech/Pharma
Funding
Total raised
$88.3M
Last stage
Public
Investors
Deerfield Management
Total raised
$88.3M
Last stage
Public
Investors
Steven Nichtberger
MD; has served as CEO, President, and Chairman of Cabaletta Bio since its founding in 2017. Also a senior fellow and professor of practice at the Wharton School of the University of Pennsylvania. Previously founding CEO of Tengion and held roles at Merck.
LinkedInMichael Milone
MD, PhD; Penn physician-scientist and co-inventor of Kymriah, the first FDA-approved CAR T cell therapy. Serves as co-chair of Cabaletta's Scientific Advisory Board.
Aimee Payne
MD, PhD; Penn physician-scientist and professor of Dermatology. Lead physician in the Autoimmune Blistering Clinic at Penn. Serves as co-chair of Cabaletta's Scientific Advisory Board.
No applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.